Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Prenetics Global Limited (NASDAQ: PRE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Prenetics files reports with the U.S. Securities and Exchange Commission under the Exchange Act, including Form 20-F for annual reporting and Form 6-K for current reports. These filings document key developments in the company’s health sciences business, its IM8 premium health and longevity brand, and its capital markets activities.
Form 6-K current reports for Prenetics frequently furnish press releases on topics such as quarterly financial results, public offerings of Class A ordinary shares and associated warrants, warrant exchange programs, strategic divestitures, and updates to capital allocation strategy. For example, 6-K filings have incorporated press releases announcing third quarter financial results, the closing of a best efforts public offering, and the cessation of new Bitcoin purchases in favor of focusing capital on IM8.
Filings also disclose capital structure details, including the terms of Class A, Class B, and Class C warrants, placement agency agreements, and warrant agency agreements. These documents provide the legal and economic terms governing warrants, exercise prices, durations, and any forced-redemption features. Investors interested in potential dilution, warrant overhang, and equity-linked instruments can review these filings to understand how Prenetics manages its capital structure.
SEC reports further capture strategic and governance events, such as notices of annual general meetings, incorporation by reference of press releases into registration statements on Form F-3 and Form S-8, and information about principal executive office locations in Charlotte, North Carolina, and Hong Kong. Certain 6-Ks also describe open market share purchases by members of the executive leadership team, offering insight into insider activity and alignment with shareholders.
On Stock Titan, these filings are updated as they are released on EDGAR. AI-powered summaries help explain the significance of complex documents, including annual reports on Form 20-F, quarterly results furnished on Form 6-K, and filings related to offerings and warrant exchanges. Users can quickly see what changed in a filing, how it affects Prenetics’ IM8-focused strategy, and where insider transactions or capital allocation decisions appear in the official record.
By reviewing Prenetics’ SEC filings alongside AI-generated insights, investors can better understand the company’s financial reporting, risk disclosures, capital allocation policies, and structural changes that shape the long-term outlook for PRE and its IM8 health and longevity platform.
Prenetics Global Limited reported that its Chief Executive Officer and co‑founder, Danny Sheng Wu Yeung, bought additional shares of the company in the open market. On November 19, 2025, he purchased 20,000 Class A Ordinary Shares at $13.00 per share, for a total purchase price of $260,000. Following this transaction, his total holdings of Class A Ordinary Shares increased to 96,412 shares. This reflects a personal capital commitment by the CEO using his own funds rather than an issuance of new shares by the company.
Prenetics Global Limited (PRE) reported that its Chief Executive Officer and co-founder, Danny Sheng Wu Yeung, bought additional company stock on the open market. On November 18, 2025, he purchased 20,118 Class A Ordinary Shares at a price of $12.02 per share, for a total of about $242,000. Following this transaction, his holdings in the company’s Class A Ordinary Shares increased to 76,412, signaling a higher personal stake in Prenetics’ future performance.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, bought 30,000 Class A ordinary shares on the open market on November 14, 2025. He paid $13.29 per share, for a total purchase price of $398,821. Following this transaction, his total holdings increased to 75,553 Class A ordinary shares of the company. This filing simply records the executive share purchase and resulting ownership level.
Prenetics Global Limited reported that its Chief Marketing Officer, Rahul Ramchand, purchased 30,000 Class A Ordinary Shares in the open market on November 12, 2025 at $13.17 per share, for a total of $395,151. Following this transaction, his holdings increased to 45,553 Class A Ordinary Shares.
The purchase was disclosed via a Form 6-K and reflects an executive open-market buy.
Prenetics Global Limited filed a Form 6‑K furnishing a press release with its unaudited financial results for the third quarter ended September 30, 2025. The filing states that this report is incorporated by reference into the company’s existing Form F‑3 and Form S‑8 registration statements. The press release is attached as Exhibit 99.1.
Prenetics Global Limited closed a best efforts public offering of 2,722,642 Class A ordinary shares, each sold together with one Class A warrant and one Class B warrant at a combined price of $16.08 per unit. The company reported gross proceeds of approximately $44 million.
The Class A and Class B warrants are immediately exercisable for up to 2,722,642 shares each at exercise prices of $24.12 and $32.16, respectively, and have a five-year term from closing. Dominari Securities LLC acted as sole placement agent; compensation was an 8% cash success fee (reduced to 4% for company-introduced investors). Prenetics also issued placement agent warrants to purchase 131,829 shares at $16.08.
Prenetics plans to use proceeds for global expansion of IM8, development and implementation of its Bitcoin treasury strategy, working capital, and general corporate purposes. The transaction was conducted under an effective Form F-3 and closed on October 28, 2025.
Prenetics Global Limited launched a primary offering of 2,722,642 Class A Ordinary Shares at $16.08 per share sold together with one Class A warrant and one Class B warrant, plus warrants to purchase up to 5,445,284 shares and Placement Agent Warrants to purchase up to 131,829 shares. Gross proceeds are $43,779,297.56 with estimated net proceeds of $40.1 million.
Each Class A warrant is exercisable at $24.12 and each Class B warrant at $32.16, both immediately exercisable and expiring five years from issuance; the warrants will not be listed and may have limited liquidity. Dominari Securities LLC acted as exclusive placement agent with fees of 8% (reduced to 4% for certain investors) and warrant coverage. Shares outstanding were 12,524,823 Class A and 1,580,972 Class B prior to the offering and will be 15,247,465 Class A and 1,580,972 Class B immediately after.
The Company intends to use proceeds to expand IM8 globally, develop and implement its Bitcoin treasury strategy, and for working capital and general corporate purposes. The filing highlights risks including immediate dilution, lack of a trading market for the warrants, PFIC considerations, and Bitcoin-related volatility and custody risks.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing the pricing and subscription of its best efforts public offering. The press release is included as Exhibit 99.1. The report is signed by Chief Financial Officer Lo Hoi Chun on October 27, 2025.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer to provide an update for October 2025. The company states that on October 27, 2025 it issued a press release announcing the pricing of its best efforts public offering. The press release describing this offering is included with the report as Exhibit 99.1.
Prenetics Global Limited launched a preliminary prospectus supplement for a primary offering of Class A Ordinary Shares and/or Pre-funded Warrants, each sold together with one Class A Warrant and one Class B Warrant. The Class A and Class B Warrants are exercisable immediately and will expire five years from issuance. The warrants and Pre-funded Warrants will be issued separately but are not being listed, so liquidity may be limited.
Dominari Securities LLC is engaged as exclusive placement agent on a reasonable best efforts basis, with cash fees of 8% of gross proceeds (reduced to 4% for company-introduced investors) and placement agent warrants equal to up to 6% of the securities sold (reduced to 2% for directed orders). Pre-funded Warrants are available to investors whose share purchases would otherwise exceed 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership. Net proceeds are intended for IM8 global expansion, development and implementation of the Company’s Bitcoin treasury strategy, working capital and general corporate purposes.